Taysha Gene Therapies announced that its Compensation Committee granted 349,000 restricted stock units to three new employees on February 2, 2026, as an inducement for employment. The RSUs will vest in four equal annual installments over four years, subject to continued service with the company.

The global Sandhoff disease treatment market is projected to grow from $260 million in 2024 to $456.42 million by 2034, with a 5.75% CAGR. North America dominates the market, and gene therapy is expected to be a key growth segment for treating this rare genetic disorder.

Taysha Gene Therapies granted five new employees options to purchase 225,000 shares of common stock under their 2023 Inducement Plan, with options vesting over four years at an exercise price of $2.84.

Taysha Gene Therapies granted a new employee an option to purchase 90,000 shares of common stock under their 2023 Inducement Plan, with an exercise price of $2.63 and a 10-year term vesting over four years.

Taysha Gene Therapies announced details for three oral presentations at the 2025 IRSF Rett Syndrome Scientific Meeting, covering updates on its TSHA-102 clinical program for Rett syndrome and a symposium on natural history data.

Taysha Gene Therapies, a clinical-stage biotechnology company, announced the pricing of a public offering of its common stock and pre-funded warrants, expected to raise approximately $200 million.

Taysha Gene Therapies, a clinical-stage biotechnology company, announced that it granted a new employee an option to purchase 45,000 shares of the company's common stock as an inducement for their employment.

Taysha Gene Therapies, a clinical-stage biotechnology company, announced that it granted stock options to three new employees as an inducement to join the company. The options have a 10-year term and will vest over four years.

Taysha Gene Therapies, a clinical-stage biotechnology company, announced that it granted stock options to three new employees as an inducement for their employment. The options have a 10-year term and will vest over four years.

Taysha Gene Therapies, a clinical-stage biotechnology company, announced that it granted a new employee an option to purchase 152,000 shares of the company's common stock as an inducement for their employment.

Taysha Gene Therapies will present data from an analysis of five non-human primate studies evaluating the delivery of AAV9 gene therapy vectors using intrathecal and intra-cisterna magna administration. The findings support the clinical potential of intrathecal administration as an effective, safe, and minimally invasive approach to deliver AAV-based gene therapies for central nervous system diseases.

Taysha Gene Therapies, a clinical-stage biotechnology company, announced that it granted a stock option to a new employee to purchase 311,000 shares of the company's common stock. The stock option has an exercise price of $2.06 per share and will vest over four years.